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Obstructive sleep apnea (OSA) is a prevalent disorder that affects not only the upper
airways but also the intrathoracic airways. In this review, we summarize the results of
studies on lung function and airway inﬂammation. We provide evidence that the
alterations in intrathoracic airways observed in OSA are not purely consequences of
mechanical trauma and oxidative stress during apneic events but have a causal role in the
structural changes associated with OSA and increasing severity of this disorder.
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Obstructive sleep apnea (OSA) is a common disorder that is
characterized by repetitive episodes of total or partial collapse
of the upper airways during sleep. If OSA is accompanied by
symptoms of excessive daytime sleepiness, tiredness, or
fatigue, the term obstructive sleep apnea syndrome is used.
According to the latest edition of International Classiﬁcation of
Sleep Disorders issued by the American Academy of Sleep
Medicine in 2014 [1], OSA is deﬁned as either the presence of
daily symptoms/disturbed breathing during sleep/comorbid-
ities together with more than 5 obstructive respiratory events
or more than 15 obstructive respiratory events, irrespective of
symptoms or comorbidities. Because of the diversity of the
diagnostic methods and criteria, the exact prevalence of OSA is
not known, but it ranges between 10% and 30% in the general
adult population [2]. Obesity, male sex, age, and craniofacial
anatomy are the major determinants of OSA susceptibility [2].
Therefore, sociodemographic variations may contribute to
diverse epidemiological results as well.
Decreased pharyngeal diameters and an increased possi-
bility of upper airway collapse are important but not the only
components of the OSA pathophysiology. Local and central
nervous control and systemic inﬂammation are also fre-
quently recognized factors. However, there has been little
attention on the role of intrathoracic airways even though the
lungs are under massive oxidative burden caused by chronic
intermittent hypoxia (CIH). It seems that the lower airways
do not just passively participate in OSA but may contribute to
the complex pathophysiology of the disease as well.
This article aims to summarize the current knowledge on
the role of lung volume and airway inﬂammation in OSA.2. Lung volumes
It has been recognized that reduced lung volumes are related to
increased OSA severity, regardless of whether the patients have
airway or parenchymal lung disease. This relationship has been
conﬁrmed both by body plethysmography [3–6] and spirometry
[7,8]. In particular, negative relationships were reported
between the severity of OSA, determined using the apnea/
hypopnea index (AHI) or respiratory disturbance index, and
expiratory reserve volume [3–6], functional residual capacity
[4,5], forced expiratory volume in one second (FEV1) [7,8], and
forced vital capacity (FVC) [7]. In line with this, a signiﬁcant
association between lung function loss and all-cause mortality
was reported in patients with OSA [9]. However, the contribu-
tion of lung volume loss to mortality was lower in patients with
sleep disordered breathing than in control subjects (6% vs. 11%,
for every 200mL decrease in FEV1) [10].
The relationship between reduced lung volume and OSA
severity needs to be interpreted carefully because BMI is aPlease cite this article as: Bikov A, et al. Role of lung volume and
Investigation (2017), http://dx.doi.org/10.1016/j.resinv.2017.08.00strong covariate for this association [7]. Obesity reduces the
functional residual capacity, especially in the supine position
[11], and is strongly associated with OSA severity [11]. However,
there are arguments that the association between lung volume
and OSA severity is independent of obesity. First, the lung
volume was reduced when patients with OSA were compared
with BMI-matched controls [6,8]; the AHI and expiratory reserve
volume were found to be related after correction for body mass
index (BMI) [4]. Second, OSA is highly prevalent in non-obese
patients with restrictive lung disease [12]. Third, reduced lung
volume leads to upper airway collapse not only in patients with
OSA but also in patients with chronic obstructive pulmonary
disease (COPD) [13] and in healthy controls [14,15].
The association between lung volumes and upper airway
collapsibility can be explained by mechanical [16] and chemical
[17] factors [18]. A higher lung volume causes the mediastinal
structures to be pulled caudally, leading to pharyngeal airway
dilation [16]. Furthermore, increased lung volume is associated
with the storage of more O2 and CO2, thus buffering blood gases
from changes in ventilation [17]. Some patients with OSA are
particularly prone to intermittent hypercapnic episodes, devel-
oping respiratory disturbances due to high loop gain [18].
Recently, we described an evening-to-morning increase in
FEV1 in OSA without any change in FVC. This very mild
bronchodilation may be caused by sympathetic bursts during
apneic periods [7], but the exact reason needs to be investi-
gated in detail. Of note, this increase was observed only in
obese patients with OSA; there were no changes in non-obese
subjects with OSA or obese control volunteers [7]. Tidal
volumes tend to decrease at sleep onset in non-OSA patients
of normal weight [19], as well as in non-OSA obese patients
[11] and patients with OSA [20].
Continuous positive airway pressure (CPAP) treatment
increases the vital capacity and functional residual capacity
in non-OSA patients [21]. In addition, increases in lung
volume are associated with lower pressures, required to
maintain upper airway patency [14]. Thus, it seems that CPAP
treatment prevents apneic episodes not only at the level of
the upper airways but also by inﬂuencing the lower airway
volumes. Of note, one study reported that long-term CPAP
treatment is associated with worsening lung function, espe-
cially in terms of markers of small-airway obstruction [22].
Only one randomized controlled trial investigated if
increasing the airway caliber with salmeterol has any effect
on AHI in OSA; however, the effect of salmeterol compared to
that of the placebo was insigniﬁcant [23].3. Airway inﬂammation
Both chronic intermittent hypoxia and vibration trauma
during snoring may induce inﬂammatory changes in the
upper airways [24]. These include neutrophilia in the nasalairway inﬂammation in obstructive sleep apnea. Respiratory
9
r e s p i r a t o r y i n v e s t i g a t i o n ] ( ] ] ] ] ) ] ] ] – ] ] ] 3lavage ﬂuid [25,26] and lymphocytosis in the pharyngeal
lavage ﬂuid [27,28]. In addition, OSA is characterized by an
increase in the nasal levels of bradykinin and vasoactive
intestinal peptide [25]. The resulting inﬂux of inﬂammatory
cells and the cytokine release may aggravate vasodilation,
squamous cell hyperplasia, and hypertrophy of mucous
glands. In addition, upper airway inﬂammation may lead to
local anesthesia, which can blunt the physiological dilator
reﬂex. Systemic inﬂammation augmented by obesity in OSA
may cause pharyngeal myopathy and inﬂuence central neu-
ronal control of the upper airway muscles [24]. Thus, upper
airway inﬂammation seems to be both a cause and conse-
quence of OSA (Fig. 1).
Vibration trauma is less likely to contribute to lower
airway inﬂammation. However, oxidative stress caused by
CIH may affect 25–70 m2 [29] of the intrathoracic airway tract.
In vitro studies have shown that intermittent hypoxia
enhances neutrophil chemotaxis and leads to the production
of matrix metalloproteinase (MMP)-2, MMP-9, interleukin (IL)-
8, platelet derived growth factor-AA, and vascular endothelial
growth factor (VEGF) by airway epithelial cells and VEGF by
bronchial smooth muscle cells [30]. Chronic intermittent
hypoxia activates nuclear factor-kappaB in mice lungs
in vivo and in monocytes of patients with OSA in vitro andFig. 1 – Upper airway inﬂammation in obstructive sleep apnea.
structural changes in the upper airways (highlighted in ellipses
addition, upper airway inﬂammation corresponds to decreased
reﬂexes and myopathy and enhances systemic inﬂammatory p
Please cite this article as: Bikov A, et al. Role of lung volume and
Investigation (2017), http://dx.doi.org/10.1016/j.resinv.2017.08.00theoretically induces the production of tumor necrosis factor
(TNF)-α, IL-6, IL-8, IL-18, and intercellular adhesion molecule
(ICAM)-1 [31]. In ovalbumin-sensitized rats, CIH induced Th1-
type airway inﬂammation and airway narrowing [32]. A
disturbed sleep proﬁle is another characteristic of OSA. In
mice, sleep deprivation exacerbated endotoxin-induced lung
inﬂammation [33,34], which suggests that sleep fragmenta-
tion may correspond to augmented airway inﬂammation.
Studies that used induced sputum for sampling showed
neutrophilia in the airways of adult [26,35–41] and pediatric
[42] patients with OSA, without any change in the eosinophil
or lymphocyte counts. In addition, in the evaluation for
soluble mediators in sputum and exhaled breath condensate
(EBC) samples, elevated levels of IL-6 [43–47], IL-8 [36,40], TNF-
α [44–46,48], ICAM [40], 8-isoprostane [43–47,49–51], H2O2
[51,52], uric acid [53], nitrate [51], leptin [41], leukotriene B4
[51,54], and cysteinyl leukotrienes [54] and decreased con-
centrations of IL-10 [44,46] and sirtuin 1 [48] were reported;
airway acidosis [38,45,51] was also reported. However, other
studies reported no differences in airway pH [55] and cystei-
nyl leukotriene [54], prostaglandin E2 [54], and erythropoietin
[56] levels.
Increased expression of inducible nitric oxide synthase
(iNOS) by airway neutrophil cells and macrophages wasSnoring and intermittent hypoxia lead to inﬂammatory and
). Mucosal edema reduces the pharyngeal diameter. In
activity of the upper airway dilator muscles via reduced
rocesses.
airway inﬂammation in obstructive sleep apnea. Respiratory
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or TNF-α, neutrophils may produce nitric oxide via iNOS [57].
Nitric oxide excess in the airways can be detected from
exhaled breath (fractional exhaled nitric oxide, FENO). FENO
was shown to be elevated in OSA in some [36,38,39,51,58–61]
but not all studies [62–66]. Because of methodological dis-
crepancies, these studies cannot be easily compared. How-
ever, taken together, a mild increase in FENO can be
concluded [67]. The levels of exhaled carbon monoxide, a
marker of oxidative stress, were also found to be elevated in
OSA [51].
Exhaled breath contains thousands of volatile molecules
and their concentration is related to airway and systemic
inﬂammation as well as metabolism [68]. The pattern of
exhaled volatile metabolites has been extensively investi-
gated in OSA using so called electronic noses [67]. Various
studies have reported altered exhaled volatile organic com-
pound patterns in adult [55,69,70] and pediatric [71] patients
with OSA. In addition, a recent study observed differences in
the exhaled volatile compound concentrations of patients
with OSA and those with COPD and the COPD–OSA overlap
syndrome [72]. The breath pattern was correlated with the
disease severity in the adults [55] and children [71]. The
exhaled volatile molecular pattern was signiﬁcantly altered
by sleep [69] and CPAP [55,73]. However, CPAP-induced
changes were signiﬁcantly dependent on comorbidities
[73]. Because of the nonspeciﬁc nature of electronic nose
measurements, the individual molecules responsible for the
differences in OSA are not known. Elevated levels of exhaled
butanol [74], toluene, ethylbenzene, p-xylene, phenylacetic
acid, hexane, heptane, octane, nonane, decane, acetone, and
isoprene [75] as well as an overnight increase in exhaled
pentane [64] were reported in OSA. In addition, CPAP with-
drawal resulted in alterations in the concentrations of
several volatile organic compounds [76].
Some studies investigated airway inﬂammation in
patients who suffered from concomitant OSA and COPD.
Upon analyzing bronchoalveolar lavage ﬂuid (BALF) sam-
ples, Wang et al. reported a higher elevation in airway
neutrophilia in the overlap syndrome than in COPD alone
[77]. In contrast, Lacedonia et al. reported similar neutrophil
counts in induced sputum samples [35]. The discrepancies
may be because of the low sample size in the latter study, as
neutrophil counts tended to be higher in the overlap group
(74.33%7 14.8) than in the COPD group (63.33%7 13.22) [35].
In the analysis of BALF cytokines, the COPD–OSA overlap
syndrome was characterized by elevated levels of TNF-α and
IL-8 compared with COPD alone [77]. In patients with severe
asthma, OSA resulted in higher levels of sputum IL-8 and
subsequent sputum neutrophilia [78].
Similar to that in the upper airways, inﬂammation in the
lungs may not only be a consequence of chronic intermit-
tent hypoxia and vibration trauma but may also contribute
to the pathophysiology of OSA. Local inﬂammatory cyto-
kines may overspill into circulation, contributing to low-
grade systemic inﬂammation, which is present in OSA [79].
It was shown that the vascular permeability index isPlease cite this article as: Bikov A, et al. Role of lung volume and
Investigation (2017), http://dx.doi.org/10.1016/j.resinv.2017.08.00increased in OSA and is signiﬁcantly related to disease
severity [80]. In line with this, exhaled and circulating levels
of 8-isoprostane were signiﬁcantly correlated with each
other [50]. However, another study found no correlation
between the circulating and sputum levels of the investi-
gated inﬂammatory mediators [80]. In conclusion, more
studies are warranted to conﬁrm or reject the overspill
hypothesis. On the other hand, airway inﬂammation may
induce airway narrowing, which has been recently con-
ﬁrmed in OSA [80]. Nevertheless, signiﬁcant associations
were reported between the magnitude of airway inﬂamma-
tion and OSA severity [38–40,43,46,48–52,60].
Obesity may aggravate airway inﬂammation. However,
studies examining airway inﬂammation in obese indivi-
duals usually did not take into consideration the possible
effect of OSA. Lacedonia et al. investigated the cellular
pattern of the induced sputum of non-OSA obese patients
and found no difference compared to that of non-OSA non-
obese controls [35]. Of note, neutrophil cell counts tended to
be higher in obese patients (43.5% 7 17.49) than in non-
obese controls (32.04% 7 12.26) [35]. In OSA, a signiﬁcant
association was found between BMI and the sputum levels
of IL-6 [80]. In line with this, two studies reported airway
neutrophilia and elevated FENO levels in obese non-OSA
subjects compared with controls [38,39]. However, both
studies concluded that OSA had an additional effect on
airway inﬂammation when the obese subjects were divided
into OSA and non-OSA groups [38,39]. In contrast, although
obesity was associated with higher EBC IL-8 and ICAM-1
levels in non-OSA subjects, OSA did not induce further
elevation of EBC IL-8 and ICAM-1 levels in obese volunteers
[40]. Finally, the levels of EBC leptin were higher in obese
than in non-obese non-OSA subjects [41].
It is not clear how treating OSA affects airway inﬂamma-
tion. On analyses of BALF samples, CPAP was found to
signiﬁcantly reduce the neutrophil count as well as TNF-α
and IL-8 levels in patients with the COPD–OSA overlap
syndrome. However, the subjects used inhaled corticoster-
oids as well, which might have inﬂuenced the results [77]. In
contrast, CPAP had no effect on sputum neutrophilia in OSA
[26,36]. In the investigation of soluble mediators, CPAP was
found to signiﬁcantly decrease the levels of IL-6 [44,81],
8-isoprostane [44,49,50,81], TNF-α [44,48,81], and nitrotyrosine
[81] and increase the IL-10 [44] and sirtuin 1 concentrations
[48] as well as pH [51] in the airways. However, other studies
have reported that CPAP treatment did not signiﬁcantly
change the exhaled carbon monoxide [51], EBC IL-6 [82],
H2O2 [51], 8-isoprostane [51], nitrate [51,82], LTB4 [51], or pH
[55,82] values. Similarly, CPAP was found to decrease FENO in
some [51,58,60] but not all [36,63] studies. A possible reason
for the inconsistent results is that CPAP therapy may itself
exacerbate airway inﬂammation due to mechanical trauma.
This is in line with its effect on airway hyperresponsiveness
[36,83,84]. Using heated humidiﬁcation with CPAP could be a
possible solution, as this is more effective in reducing airway
[36] and nasal [85] inﬂammation. Upper airway surgery did
not change the EBC IL-6 levels or EBC pH signiﬁcantly [82].airway inﬂammation in obstructive sleep apnea. Respiratory
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Fig. 2 – Elements of airway inﬂammation in obstructive sleep apnea. Chronic intermittent hypoxia (CIH) induces production of
pro-inﬂammatory cytokines, including interleukin (IL)-6, IL-8, and tumor necrosis factor (TNF)-alpha as well as VEGF. These
induce neutrophil cell and lymphocyte inﬂux, which potentiate oxidative and nitrosative stress, bronchoconstriction, and
airway acidiﬁcation and accelerate airway inﬂammation through positive feedback mechanisms. In addition, increased
production of VEGF and nitric oxide leads to bronchial vasodilation. This not only facilitates the inﬂux of circulating
inﬂammatory cells toward airway mucous but also allows overspill of airway inﬂammatory cytokines and markers of
oxidative and nitrosative stress into circulation.
r e s p i r a t o r y i n v e s t i g a t i o n ] ( ] ] ] ] ) ] ] ] – ] ] ] 54. Summary
Obstructive sleep apnea may trigger lower airway inﬂamma-
tion primarily through intermittent hypoxia and oxidative
stress and secondarily through vibration trauma and sleep
fragmentation. This inﬂammation is characterized by type
1 cytokines and airway neutrophilia (Fig. 2). Obesity, a major
co-factor in OSA pathophysiology, may directly affect airway
inﬂammation and may also worsen overnight hypoxia [18],
accelerating OSA-induced changes in the airways. The reduc-
tion in lung volumes, either induced by parenchymal lung
disease or obesity, would worsen OSA due to anatomical,
chemical, and neuronal factors.
Currently, information on whether treating OSA with
CPAP improves airway function and inﬂammation is limited.Please cite this article as: Bikov A, et al. Role of lung volume and
Investigation (2017), http://dx.doi.org/10.1016/j.resinv.2017.08.00This highlights the need for the development of pharmaco-
logical anti-inﬂammatory treatments for OSA. However, to
date, data on the effects of these drugs are very limited.Funding
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